Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment
- PMID: 16295535
Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment
Abstract
The therapeutic effect of a subcurative dosage of praziquantel (PZQ) on Schistosoma mansoni infected mice and resistance to challenged worm infection after treatment were assessed and compared with conventional treatment using a curative dosage of PZQ. S. mansoni infected mice were treated with PZQ at a curative dosage (600 mg kg(-1)) or a subcurative dosage (300 mg kg(-1)) at 9 weeks after infection. Untreated mice and non-infected mice were added as controls. The therapeutic effect of the drug was evaluated in terms of the mortality of mice after treatment, and the parasitological and pathological findings in mice sacrificed at 1 week, 1 month, or 3 months after treatment. Another sample of mice was not killed but challenged with S. mansoni cercariae at 1 week, 1 month, or 3 months after treatment. Resistance to re-infection was evaluated by the extent of challenged worm reduction. In conclusion, there was no significant difference in mortality, or parasitological and pathological findings between mice treated with PZQ at the two dosages. However, resistance to challenged worm infection was more sustained in the group treated with subcurative dose PZQ, especially at 3 months after treatment.
Similar articles
-
Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo.J Helminthol. 2002 Dec;76(4):327-33. doi: 10.1079/JOH2002135. J Helminthol. 2002. PMID: 12498638
-
Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates.APMIS. 2006 Jul-Aug;114(7-8):480-91. doi: 10.1111/j.1600-0463.2006.apm_380.x. APMIS. 2006. PMID: 16907853 Clinical Trial.
-
Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination.Int J Parasitol. 2004 Jul;34(8):971-7. doi: 10.1016/j.ijpara.2004.04.005. Int J Parasitol. 2004. PMID: 15217736
-
Resistance of Schistosoma mansoni to praziquantel: is there a problem?Trans R Soc Trop Med Hyg. 2002 Sep-Oct;96(5):465-9. doi: 10.1016/s0035-9203(02)90405-0. Trans R Soc Trop Med Hyg. 2002. PMID: 12474468 Review.
-
Efficacy of single dose praziquantel against Schistosoma mansoni in East Africa: a systematic review and meta-analysis.Sci Rep. 2025 Feb 7;15(1):4642. doi: 10.1038/s41598-024-84621-8. Sci Rep. 2025. PMID: 39920188 Free PMC article.
Cited by
-
A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection.Parasit Vectors. 2019 Jun 17;12(1):304. doi: 10.1186/s13071-019-3563-z. Parasit Vectors. 2019. PMID: 31208446 Free PMC article.
-
Immunodiagnostic methods: what is their role in areas of low endemicity?ScientificWorldJournal. 2012;2012:593947. doi: 10.1100/2012/593947. Epub 2012 Dec 17. ScientificWorldJournal. 2012. PMID: 23319886 Free PMC article. Review.
-
Effect of Lactobacillus sporogenes (probiotic) on certain parasitological and molecular aspects in Schistosoma mansoni infected mice.J Parasit Dis. 2016 Sep;40(3):823-32. doi: 10.1007/s12639-014-0586-4. Epub 2014 Oct 30. J Parasit Dis. 2016. PMID: 27605791 Free PMC article.
-
Parasitological and Biochemical Efficacy of the Active Ingredients of Allium sativum and Curcuma longa in Schistosoma mansoni Infected Mice.Molecules. 2021 Jul 27;26(15):4542. doi: 10.3390/molecules26154542. Molecules. 2021. PMID: 34361695 Free PMC article.
-
Evaluation of leishmanicidal activity and cytotoxicity of Ricinus communis and Azadirachta indica extracts from western Kenya: in vitro and in vivo assays.BMC Res Notes. 2015 Nov 5;8:650. doi: 10.1186/s13104-015-1605-y. BMC Res Notes. 2015. PMID: 26541197 Free PMC article.